By proceeding, you agree to our Terms of Use and Privacy Policy.
Executive Director
#covid19 #pfeproud #vaccines #covalentfirst #andproteindegradationTalks
#NorthAmerica
My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution
CEO and Owner
#crm197 #finabio #vaccines
Dr. Andrew Lees, founder and Chief Scientific Officer of Fina Biosolutions, holds over 20 patents and is the author or co-author of more than 60 peer-reviewed papers. He holds a B.S. in Chemistry from
SVP Biology
#immunology #vaccines
#Europe
Anne Goubier is currently working as SVP Biology at Molecular Partners.
VP, Preclinical Biology
#Immunology #vaccines #autoimmunedisease
Highly strategic and innovative senior leader with 23 years of global drug development experience across early, translational and late stage in Biologics.
Professor
#vaccines #molecularbiology
Dr. Chackerian is a Professor at the University of New Mexico. His work focuses on the use of virus-like particles to development vaccines for infectious and chronic diseases.
Professor – Vaccine Design & Delivery
#Drugdelivery #Vaccines
Camilla Foged is a Professor of Vaccine Design and Delivery at the University of Copenhagen. Her specialties are research interests are lipid- and polymer based nanoparticulate delivery systems for nu
Professor of Vaccine Design and Delivery
#drugdelivery #vaccines #invitro
Camilla is a professor with experience in University Teaching (Pharmaceutics) and research related to delivery of biomacromolecules (Pharmaceutics).
Global regulatory CTA Team Lead, Associate director at CSL Behring
#Clinicaldevelopment #Vaccines
Christel Gremion Viatte leads currently the Global Regulatory Affairs CTA group at CSL Behring. She has 16 years experience in management of global clinical trials and in development of clinical trial
Director of Analytical Development
#Biotechnology #Vaccines
Highly motivated CMC Scientific Director working within the field of ATMPs and Gene Therapy. Experienced in viral / vector manufacturing processes, analytical development, quality/QC and product devel
Chief Executive Officer and President
#imunon #vaccines #mycompany #immunooncology
Corinne Le Goff’s has dedicated her career to delivering on the promise of a targeted approach to disease prevention and therapies, to discover and develop medicines for people with serious and life-t
Partner
#immunology #vaccines #biology
#Northamerica
David Kaufman is currently working as Partner at Third Rock Ventures.
Chief Scientific Officer
Accomplished scientist, project team leader and head of research and development with a total of 24 years of research experience, including 20 years in the biotechnology industry.